Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GlaxoSmithKline

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune response s across all adult age groups in Phase 2 trial

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

One of the world's most closely watched coronavirus vaccine programs reported positive data on Monday from a mid-stage clinical trial, paving the way for the start of a massive human trial that could allow the shot to be authorized before the end of this year. Sanofi and GlaxoSmithKline, two of the largest vaccine-makers in the world, said in a press release that their experimental coronavirus vaccine led to strong immune responses across all ages in a study that enrolled 722 volunteers. It's a much-needed piece of positive news for the two industry leaders, which saw their vaccine effort delayed by disappointing data announced in December, and have fallen far behind rivals like Moderna, Pfizer-BioNTech, and Johnson & Johnson.

Sanofi and GlaxoSmithKline say their COVID-19 vaccine triggers a strong immune response, bolstering the late-comer program's potential as a booster shot

The two drugmakers say it might be most useful as a booster shot.

Sanofi and Glaxo Are Back With a Covid-19 Vaccine

You might want to add this international blue-chip stock to your portfolio.

Is Sanofi a Good Buy in 2021?

AstraZeneca

The companies have a promising RSV candidate.

Could AstraZeneca and Sanofi Win Big in RSV?

PARIS and PALO ALTO, Calif., May 6, 2021 /PRNewswire/ -- Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine.

Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research

Sanofi (SNY) CEO Paul Hudson on Q1 2021 Results - Earnings Call Transcript

Sanofi SA (NASDAQ: SNY) stock climbed after its Q1 earnings beat earnings expectations and stuck to its full-year guidance, as well as reported progress on its delayed COVID-19 vaccine efforts. Earnings: Overall sales increased by 2.4%, attributed mainly to Dupixent's success, with vaccines also contributing with a 5.3% rise in sales to €915 million.

Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran

AbbVie

British American Tobacco

Canadian Natural Resources

Chevron

Enbridge

Coca-Cola

Novartis

Realty Income Corp

Pembina Pipeline

AT&T

TC Energy

Unilever

Kiplinger "insights for investors" online first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 4/26/21 flagged 13 yields ripe with upside. These International “Dividend Aristocrats” have raised dividends at least five straight years (Canadian), 10 years (European Union), or 25 years (U.S. companies).

Update: 91 'Top Dividend Stocks On Earth' For May

Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.

Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View

The French pharma giant, which has fallen behind in the Covid-19 vaccine race, said results from a Phase 2 study into its candidate with GlaxoSmithKline are expected next month.

Sanofi Beats Earnings Estimates and Reveals Covid-19 Vaccine Progress

Sanofi confirmed its 2021 targets after it posted stronger-than-expected first quarter results as sales of its star eczema treatment as well as flu and polio vaccines helped offset a dip in cough and cold treatments dented by lockdowns.

Eczema treatment and vaccines lift Sanofi first quarter results

Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER

Moderna

As the demand for mRNA-based COVID-19 vaccines persists, Sanofi SA (NASDAQ: SNY) has entered an agreement with Moderna Inc (NASDAQ: MRNA) to manufacture its COVID-19 vaccine in the U.S. The agreement marks the third different company Sanofi has paired with to manufacture a COVID-19 vaccine since their effort to develop a shot faced significant setbacks.

Sanofi Steps In For Fill-Finish 200M Doses Of Moderna's COVID-19 Vaccine

The shots could be geared towards children, new variants or boosters.

Moderna Receives Vaccine-Making Boost As Sanofi Signs Up To Manufacture 200 Million Doses For Americans

French drug maker Sanofi S.A. has agreed to make Moderna Inc.'s COVID-19 vaccine at its site in Ridgefield, New Jersey, and will fill and finish up to 200 million doses starting in September.

Sanofi agrees to make Moderna COVID-19 vaccine in the U.S. starting in September

BRIDGEWATER, N.J., April 26, 2021 /PRNewswire/ -- Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna´s COVID-19 vaccine, supporting the COVID-19 pandemic and vaccine supply needs.

Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces agreement with Sanofi for fill/finish manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc's (NASDAQ: AZN) monoclonal antibody (mAb) nirsevimab has reached its primary endpoint in a Phase 3 trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants. The data comes earlier than anticipated; regulatory submissions for all-infant indications are expected to begin in 2022.

Sanofi-AstraZeneca's Nirsevimab Hits Primary Endpoint Goal In Late-Stage RSV Disease In Infants

Bayer AG

Biogen

Imperial Brands PLC

Lockheed Martin

Merck

Philip Morris

Roche Holding AG

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). e are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The May 2021 Heat Map

Amgen

Bristol-Myers

Regeneron Pharmaceuticals

Replimune Group Inc

Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.

Analysts See Plenty of Upside for Replimune

Sanofi's (SNY) new cancer drug, Sarclisa, gets second approval for treating multiple myeloma patients in Europe within a year.

Sanofi (SNY) Gets Label Expansion Nod for Sarclisa in Europe

SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a leading European drug discovery and development company, for EVT801, a small-molecule, first-in-class oncology drug candidate. Kazia expects to launch a phase I clinical trial of EVT801 in CY2021.

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”) in connection with the public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum dated 10 February 2021 (the “Offer Memorandum”), approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) on 10 February 2021 and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) on 11 February 2021. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication or distribution would be unlawful. Terms not defined in this press release will have the meaning as set forth in the Offer Memorandum.

Sanofi completes Kiadis acquisition

This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 16, paragraph 1 and 2 and Article 17 paragraph 1 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the “Decree”) in connection with the intended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum dated 10 February 2021 (the “Offer Memorandum”), approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) on 10 February 2021 and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) on 11 February 2021. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication or distribution would be unlawful. Terms not defined in this press release will have the meaning as set forth in the Offer Memorandum.

News for Sanofi Stock (SNY)